Prostate cancer is the most common type of cancer in men in the United States. In 2023, it is estimated that there will be over 260,000 new cases of prostate cancer diagnosed in the United States. While prostate cancer is often treatable, it can be fatal in some cases.
A new study published in the journal JAMA Oncology has found that prostate cancer mortality in higher-risk localized disease is lowest with surgery. The study looked at data from over 100,000 men with prostate cancer who were diagnosed between 2004 and 2013. The researchers found that men who had surgery had a significantly lower risk of death from prostate cancer than men who received other treatments, such as radiation therapy or hormone therapy.
The study also found that the benefits of surgery were greatest for men with higher-risk localized disease. Higher-risk localized disease is defined as prostate cancer that is confined to the prostate gland but has other features that make it more likely to spread, such as a high Gleason score or a high tumor stage.
The researchers concluded that surgery is the best treatment option for men with higher-risk localized prostate cancer. They also noted that surgery is a safe and effective treatment for most men.
The results of this study are important because they provide strong evidence that surgery is the best treatment option for men with higher-risk localized prostate cancer. This information can help men and their doctors make informed decisions about their treatment options.